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Abstract
Neurological disorders are a massive challenge for modern medicine. Apart from the fact
that this group of diseases is the second leading cause of death worldwide, the majority
of patients have no access to any possible effective and standardized treatment after
being diagnosed, leaving them and their families helpless. This is the reason why such
great emphasis is being placed on the development of new, more effective methods to
treat neurological patients. Regenerative medicine opens new therapeutic approaches in
neurology, including the use of cell-based therapies. In this review, we focus on summa-
rizing one of the cell sources that can be applied as a multimodal treatment tool to over-
come the complex issue of neurodegeneration—mesenchymal stem cells (MSCs). Apart
from the highly proven safety of this approach, beneficial effects connected to this type
of treatment have been observed. This review presents modes of action of MSCs,
explained on the basis of data from vast in vitro and preclinical studies, and we summarize
the effects of using these cells in clinical trial settings. Finally, we stress what improve-
ments have already been made to clarify the exact mechanism of MSCs action, and we
discuss potential ways to improve the introduction of MSC-based therapies in clinics. In
summary, we propose that more insightful and methodical optimization, by combining
careful preparation and administration, can enable use of multimodal MSCs as an effec-
tive, tailored cell therapy suited to specific neurological disorders.
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1 | INTRODUCTION
Injury of the nervous system leads to a cascade of events that even-
tually ends with neuronal loss and acute or chronic dysfunction. Such
processes can be caused by neurodegeneration (eg, amyotrophic lat-
eral sclerosis [ALS], Parkinson's disease [PD], and Alzheimer's disease
[AD]), autoimmunological reactions (multiple sclerosis [MS]), ische-
mia (stroke), mechanical injury (traumatic brain injury [TBI], spinal
cord injury [SCI]), and other factors (drug-resistant epilepsy [DRE],
cerebral palsy [CP]).1-3 These diseases impose serious economic and
financial burdens on patients, their families, and society as a whole.
Over several years, myths related to the lack of neurogenesis
de novo and lymphatic drainage in the nervous system as well as
regarding the immune-privileged state of the nervous system have
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been debunked.4,5 Thanks to recent research, the current view of
the central nervous system includes a system that is relatively able
to recover. As many diseases and injuries of the nervous system are
still untreatable or not efficiently curable by standard medical and
pharmaceutical practices, alternatives featuring regenerative medi-
cine might overcome existing barriers.6 Transplantation of cells and
tissues into the nervous system, which was first performed in the
1980s, aims to promote regeneration through direct replacement of
lost cells.7 Obtained fetal tissues and implants derived from various
sources of neural progenitor cells (NPCs) and neurons still evoke
debate around ethical and safety issues.8 Apart from the source of
new neurons, NPCs have also been shown to have immunomodula-
tory characteristics.9 Nevertheless, discontinuation of the need for
treatment with immunosuppressive drugs that comes with alloge-
neic treatment diminishes or even removes the positive effects of
therapies.10 Recently, autologous transplantation strategies featur-
ing iPSC technology have appeared.11 However, clinical translation
of this approach is far from realized because the tumorigenic and
long-term immunogenic potentials of these cells have not been
tested.
Strategies for treating diseases and injuries of nervous system
appoint a less direct but still beneficial source of cells for transplant to
cure such yet incurable diseases—mesenchymal stem cells (MSCs).
They can be easily obtained from tissues, expanded ex vivo, and
transplanted in an autologous or allogeneic manner.12 Due to their
immunomodulative properties, MSCs can resolve inflammation trig-
gered by injury or degeneration.13 Via their secretome, they can sup-
port the survival of neurons and affect the regeneration of tissue loss
by influencing local neurogenic niches.14
In this review, we introduce unique MSC characteristics valu-
able for the repair of the nervous system in various diseases based
on in vitro and preclinical studies. Taking into consideration the
clinical application of MSCs, this review is focused only on the
properties of human MSCs from the three most common sources:
bone marrow (BM), Wharton's jelly (WJ), and adipose tissue (AT).
Clinical studies will be reviewed, focusing on their safety and effi-
cacy. We will also explore discrepancies between clinical studies
and suggest potential ways to enhance the effectiveness of MSC
therapies.
This narrative review was prepared based on publications found
in the PubMed database using the following keywords: MSCs, ner-
vous system, neurodegeneration, and neurological diseases (or each
disease specifically, eg. PD, AD, epilepsy, and SCI). For clinical trials,
the name of each neurological disease and the term “mesenchymal
stem cells” were used as key words, adding “clinical trial” as a filter in
the PubMed database. Additionally, clinical trials were filtered from
the ClinicalTrials.gov database.
2 | MSCs AND THEIR PROPERTIES
MSCs, which possess self-renewal potential and multipotent proper-
ties, can be found in neonatal and adult tissues. These adherent,
fibroblast-like cells were first isolated from BM in 1970 by Fri-
edenstein et al.15 Over the years, these cells have been called by many
names, such as mesenchymal stromal stem cells, multipotent adult
progenitor cells, medicinal signaling cells, and mesenchymal progenitor
cells (MPCs). Currently, MSCs is the most common terminology, but is
sometimes used interchangeably with mesenchymal stromal stem cells
to underline their origin from the nonhematopoietic compartment of
BM. In addition, MPCs are occasionally presented as a distinct
population.16
Apart from BM, MSCs have also been identified in AT,17 umbilical
cord blood,18 the umbilical cord lining,19 subendothelial layers,20 the
perivascular zone,21 WJ,22 dental pulp,23 synovial fluid24 and the
synovial membrane,25 amniotic fluid,26 fetal liver27 and even urine28
or endometrium.29 Recently, pericytes with MSC-like characteristics
were also found in the brain.30
Independent of the tissue source, the isolated cells need to
express common characteristics to be defined as MSCs. As no single
marker has been specified for these cells yet, analysis of a set of sur-
face antigens needs to be performed. According to the International
Society for Cellular Therapy gold standard, MSCs need to be positive
for CD73, CD90 and CD105 (all >95%) and negative for CD34, CD45,
CD11b/integrin alpha M or CD14, CD79 alpha or CD19, and HLA
class II (all <2%).31 The status of HLA class II can change upon cell
stimulation but the expression of costimulatory molecules, such as
CD40, CD80, CD86, CD134, and CD142, cannot be changed.32,33
Moreover, the multipotent character of MSCs needs to be proven by
their differentiation into adipocytes, chondrocytes, and osteocytes
when cultured in vitro.31 Some studies suggest that MSCs are also
capable of transdifferentiating in vitro to cells outside mesenchymal
lineages, such as neural and glial cells, cardiomyocytes, skeletal
myocytes, hepatocytes, and endothelial cells; however, these studies
have been questioned by recent findings.34,35
As a distinct entity from the multipotency understood as differen-
tiation potential per se, the term functional multipotency has been
coined.36 This characteristic refers to the ability of different types of
stem cells to exert pleiotropic influence on injured tissue to support
the maintenance of homeostasis, which remains crucial during devel-
opment but also during tissue repair after injury. Interestingly, studies
have shown that sustaining the stemness of MSCs by incorporating
specially adjusted scaffolds can highly augment the therapeutic
Significance statement
This concise review summarizes the results of preclinical
and clinical trials in neurological diseases of different etiolo-
gies. This review focuses on possible mechanisms of action
of mesenchymal stem cells (MSCs) but also discusses
approaches to augment their effects. A summary of the
properties of MSCs reveals their broad therapeutic poten-
tial, which can orchestrate regenerative processes after neu-
ral injuries.
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potential of MSCs in treating spinal cord injuries.37 Such results
should encourage abandonment of the uncertain approach of using
transdifferentiated cells.
The most key and characteristic feature of MSCs is their broad
secretome, which can influence tissue regeneration. It has been
shown that MSCs can produce many immunomodulatory,
proangiogenic, tissue remodeling, antiapoptotic, growth, and trophic
factors that can support survival of host cells, reconstruction of
injured tissue and activation and differentiation of local progenitors.14
However, depending on the source of MSCs, they can differ in their
properties.38-40
2.1 | Differences between sources
Although MSCs from various sources share common characteristics,
some differences can be found between them. These variations in
MSC populations may reflect particular regional properties of the
niches from which they originate.41 MSC features are also susceptible
to variations between cell culture conditions and isolation protocols.
It has been shown that MSCs obtained from the same patient can
vary in their properties between isolations. Additionally, discrepancies
between different subpopulations of BM-derived MSCs (BM-MSCs)
have been shown.42 In the case of Wharton's jelly-derived MSCs (WJ-
MSCs), depending on the chosen isolation method (isolated enzymati-
cally by collagenase, trypsin, or hyaluronidase, or by extraction directly
from explants), cells can slightly differ in features such as the expres-
sion of pluripotency markers and cell proliferation rates.43 However,
in some reports, it was noted that autologous MSCs differ from those
obtained from healthy donors and that such differences can influence
the final outcomes of therapies.44
Amable et al. published three studies in which the properties of
BM-MSCs, adipose tissue-derived MSCs (AT-MSCs) and WJ-MSCs
were analyzed in different culture conditions (medium supplemented
with fetal bovine serum or platelet-rich plasma [PRP]) or during differ-
entiation.38-40 They confirmed that the higher proliferative potential
of WJ-MSCs compared to cells from other sources was independent
of cell culture conditions.45,46 AT-MSCs have a moderate proliferation
rate, and BM-MSCs have the lowest proliferation rate. Authors have
shown the influence of the cell culture on MSCs secretome. AT-MSCs
and BM-MSCs cultured in fetal bovine serum (FBS) produced high
amounts of extracellular matrix (ECM) components, which was not
observed for WJ-MSCs. Only AT-MSCs were able to produce collagen
(I, II, and III). However, supplementation of medium with PRP compen-
sated for these differences, although AT-MSCs were still the only pro-
ducers of collagen II and IV. Independent of cell culture conditions,
BM-MSCs maintained their highly proangiogenic features. AT-MSCs
cultured in PRP had lower secretion than those cultured in FBS while
demonstrating the most pronounced proangiogenic characteristics.
Amable et al. also showed that in nonstimulated conditions, WJ-MSCs
produce higher amounts of chemokines able to attract a wide range
of inflammatory cells (chemokine ligand 5, monocyte chemotactic pro-
tein 1 [MCP-1], and interferon gamma-induced protein 10) and
interleukin (IL)-6 than other types of MSCs. The high expression of IL-
6 can be crucial in treating liver fibrosis.47 In PRP-supplemented
media, IL-6 secretion by BM-MSCs was significantly increased. In
other studies, functional tests with phytohemagglutinin-activated T
lymphocytes or peripheral blood mononuclear cells have shown that
BM-MSCs are the most immunosuppressive cells. This feature has
been preserved independently of cell culture conditions.45,48,49 Inter-
estingly, Amable et al. also evaluated how the levels of secreted
chemokines, cytokines, ECM proteins, proangiogenic factors, and
growth factors changed in differentiated cells. Those experiments
have shown that some characteristics are preserved, for example, high
expression of vascular endothelial growth factor (VEGF) by BM-MSCs
and very low expression of ECM proteins by WJ-MSCs, whereas
some of the characteristics dramatically changed, for example, expres-
sion of interleukins or collagen II by differentiated AT-MSCs.40 These
results show that the differentiation of cells can influence some prop-
erties of MSCs. These findings also underlie the importance of cell cul-
ture conditions on the final properties of cells that can be later
administered to patients.
3 | MSCs IN NEURODEGENERATION AND
BRAIN INJURY—PRECLINICAL TRIALS
The previously mentioned features of MSCs make them a perfect tool
in cellular therapies for pathological processes in the nervous system
driven by excessive inflammation and neurodegeneration. MSCs
secrete a variety of factors, including neurotrophic factors.50 MSCs
from different sources can also differentiate into neuronal lineages by
forming primary neurospheres; however, only WJ-MSCs and BM-
MSCs could form secondary neurospheres.51 Moreover, differentiated
WJ-MSCs secreted more neurotrophic factors than BM-MSCs and
AT-MSCs.51
3.1 | Routes of MSC transplantation
Preclinical studies have established ways of MSC implementation via
intravenous, intra-arterial, intrathecal, intranasal, intraperitoneal, intra-
spinal, intracerebroventricular, intracerebral, or direct administration
to particular structures. The route of administration is important
because it determines the number of successfully grafted cells in the
injured site, which can be correlated with therapeutic outcome.52,53
Additionally, taking into consideration that neurological disorders may
not be localized, indirect administration, for example, intrathecal injec-
tion, may be of great importance.
To understand the pros and cons of each route of administration,
an invaluable tool is cell tracking. Various methods have been devel-
oped for intravital imaging.54 Studies have shown that although the
most feasible method of MSC transplantation is through intravenous
injection, in such conditions, most of the cells become trapped in the
lungs.55 Nevertheless, such entrapped MSCs can release microvesicles
and immunomodulative factors and affect the overall state of the
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patient by modulating peripheral immune cells.56 Moreover, cell track-
ing can visualize MSC migratory potential.
3.2 | Active migration of MSCs toward injury
Once administered indirectly, MSCs need to actively migrate to the
injury region. Active migration of MSCs is possible due to the expres-
sion of receptors and cell adhesion molecules. Pivotal roles are played
by receptors, integrins, selectins and proteolytic enzymes.54 One of
the pathways crucial for MSC migration is the METR/HIF-1/CXCR4
pathway.57 It was shown that preconditioning MSCs with stroke
patients' sera enhanced the METR/HIF-1/CXCR4 pathway and
increased the migratory potential of MSCs, which translated into
improved recovery in a transient middle cerebral artery occlusion
(tMCAO) stroke model in rats.57 Important chemoattractants that can
enhance MSCs to regions of injury in the brain are MCP-1 and stromal
cell-derived factor-1 (SDF-1). In a study by Lee et al., it was shown in
the MCAO rat model of stroke that MCP-1 and SDF-1 have both
region- and time-dependent differential expression, which directs
intravenously injected MSCs to migrate either to the cortex 1 day
after injury or to the striatum in later days.58 That MSC migration
dependent on CXCR4 receptor expression was also shown in elegant
in vitro studies with microfluidics systems.59
3.3 | MSCs act through immunomodulation
MSCs are mostly recognized as immunomodulatory cells that can bal-
ance inflammation in the tissue environment by upregulating anti-
inflammatory signaling and decreasing pro-inflammatory signaling and
thus regulate immunological cells such as lymphocytes, macrophages
or microglia and astrocytes.60,61 MSCs can influence inflammation by
secreting soluble factors or direct cell-cell contact. MSCs constitu-
tively or upon stimulation secrete indoleamine 2,3-dioxygenase, trans-
forming growth factor beta, hepatocyte growth factor, IL-6 and IL-10,
prostaglandin E2, heme oxygenase 1 and soluble HLA-G5.13
Inflammation is an integral part of pathological processes that
emerge in the nervous system. Depending on the mechanism of injury
or neurodegeneration, the innate or adaptive system plays a more
important role. Due to their migratory potential, MSCs can migrate to
the site of injury and, due to their immunomodulatory properties,
decrease inflammation. Excessive inflammation in the brain is the
most devastating force causing degeneration of the central nervous
system.62,63 Acute injuries due to ischemia (hypoxia-ischemia enceph-
alopathy [HIE] and stroke), mechanical-driven trauma (such as TBI) or
progressive neurodegeneration lead to moderate activation of
microglia followed by activation of astrocytes, the main sources of
inflammatory cytokines.64 If this state persists, damage to the blood-
brain barrier (BBB) occurs, and intensified inflammation appears due
to the migration of peripheral immune cells (lymphocytes and mono-
cytes).65 Such processes suppress neurogenesis and endogenous
repair.66 Thus, MSCs could be a perfect tool in brain injuries, as they
can modulate the inflammatory state. It has been shown that MSCs
can attenuate microgliosis and astrogliosis in rats with induced HIE,
SCI, or epilepsy.67-69 MSCs can also suppress the proliferation and dif-
ferentiation of B lymphocytes.70 Moreover, transplanted MSCs can
switch activated M1-phenotype microglia to the regenerative M2
phenotype.71-73 Additionally, in an AD model of APP/PS1 double
transgenic mice, transplantation of MSCs led to reduced β-amyloid
(Aβ) peptide deposition by microglia but without secretion of
proinflammatory factors.73-75 MSCs have also been shown to improve
BBB integrity in a rat TBI model.76 This effect was mainly mediated by
the activity of metalloproteinase inhibitor 3 (TIMP-3) released
by MSCs.
3.4 | MSCs support regeneration through their
neurotrophic activity
Decreasing the inflammation status may contribute to the onset of
direct repair of neuronal circuitry and activation of endogenous neu-
rogenesis by MSCs. It has been shown that timing of extinguished
inflammation and activation of local progenitors overlap in MSC-
treated mice with induced HIE.71 MSCs and MSC conditioned media
(MSC CM) alone can activate local progenitors in healthy adult rat
brains and their differentiation into immature neurons in the sub-
ventricular zone (SVZ).77 However, injection of MSC CM into the
brain alone cannot protect the brain against inflammation and has a
short-lasting effect. Moreover, repeated transplantations of MSCs in a
D-galactose-induced mouse model of cognitive decline have shown
functional improvement measured in cognitive tests by enhancing
synaptic plasticity and endogenous neurogenesis.78 This effect was
shown to be mediated by activation of the mitogen-activated protein
kinase-ERK-CREB signaling pathway in the aged hippocampus. Trans-
plantation of MSCs also rescued long-term potentiation impairment in
aging mice through impacts on electrophysiology.
The neuroregeneration ability of MSCs is also based on the secre-
tion of a wide range of paracrine substances by host cells and MSCs.
Several growth factors are secreted by MSCs: brain-derived neuro-
trophic factor (BDNF), nerve growth factor, insulin-like growth factor
1, glial cell-line-derived neurotrophic factor (GDNF) and VEGF.79-81
The neuroprotective function of transplanted MSCs is based on a
reduction in neuronal sensitivity to glutamate receptor ligands and
altered gene expression, suggesting a link between the therapeutic
effects of MSCs and the activation of cell plasticity in damaged ner-
vous structures.82 Experimental models proved that the MSC secret-
ome promotes axonal growth and neuroprotection and minimizes
cavity formation in SCI.83,84 Neurotrophic and neurotropic effects of
MSCs were also clearly presented in some elegant ex vivo studies
employing adult rat dorsal root ganglia organotypic cultures.37,85
Interestingly, this type of culture can be used to decipher other
effects of MSCs on injured tissue, for example, immunomodulation.37
Lu et al. investigated the nature of chronic scars and their ability to
block axon growth. Chronically injured spinal cord axons can regener-
ate through the gliotic scar in the presence of local growth-stimulating
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factors.86 MSCs may provide a source of growth factors to enhance
axonal elongation across spinal cord lesions and minimize cavity for-
mation in SCI.68,87 Interestingly, growth factor secretion, neuro-
genesis, and survival of stem cells are improved when MSCs are
harvested under hypoxic conditions.88
3.5 | MSC modifications and neuronal priming
Despite their innate, multipotent character, MSCs can be even more
perfectly tailored to the exact type of injury. This advancement can be
achieved by appropriate MSC preparation for the specific environ-
ment before transplantation. Up to date, various ways of priming of
MSCs with cytokines, hypoxia, pharmacological agents, biomaterials,
and other molecules have been established (comprehensively
reviewed in Reference 89).
In some neurological disorders, such as PD, ALS, and stroke, gene
therapies are proposed as a method of treatment.90 One of the chal-
lenges of such approaches is the delivery of genes of interest, espe-
cially in nonfocal neurodegenerations. MSCs can thus serve as carriers
for genes whose expression is needed in specific neurological disor-
ders: GDNF (PD and ALS),91,92 VEGF (PD),93 GDNF and VEGF
(ALS),94 BDNF (Huntington's disease [HD], SCI, and stroke),95-97 con-
served dopamine neurotrophic factor,98 and PlGF (stroke).99 It has
been shown that modified cells have a more pronounced therapeutic
effect than unmodified MSCs. This result stems from the fact that
despite the desired alterations, modified MSCs maintain the rest of
their characteristics, such as a capacity for immunomodulation. How-
ever, more studies are needed to determine whether transient deliv-
ery of such growth factors is sufficient or repeated transplantation is
needed depending on the treated disease. In contrast, MSCs can also
be used to decrease undesirable genes to promote repair. One study
has shown that modification of MSCs with lentiviral RNAi down-
regulating adenosine kinase, the major adenosine-removing enzyme,
may be beneficial for treating epilepsy. Indeed, transplantation of such
modified MSCs resulted in a decrease in seizures, and this effect was
strictly connected to elevated levels of adenosine.100 Moreover, mod-
ified MSCs transplanted directly into the injury site demonstrated a
better ability to promote neuron survival and decrease damage than
unmodified MSCs.101
Additionally, taking into consideration the impact of miRNAs in
the regeneration of tissue, MSCs can serve as carriers of different
miRNAs to the nervous system.102,103 However, in some cases, a
decrease in miRNAs can be beneficial. For example, in the case of SCI,
suppression of miR-383 enhances the therapeutic potential of MSCs
in SCI.104
There have also been studies with an established cell line, SB623
hBM-MSCs (SanBio Inc.), which overexpresses the NOTCH 1 intracellu-
lar domain. These cells transplanted in preclinical trials have ameliorated
damage in models of PD or after TBI,105,106 probably due to enhanced
neuropoietic and proangiogenic activity.107,108 Moreover, in a TBI model,
transplanted SB623 cells formed “biobridges” between the neurogenic
niche and the site of injury.106 This effect has been correlated with
metalloproteinase-9 (MMP-9) activity. Functional formation of these bio-
bridges can play an important role not only in TBI but also in ischemic
injuries in the brain.109 These results can partially explain the regenera-
tive potential of SB623 cells in clinical trials with stroke patients.110 Cur-
rently, a clinical trial is underway in which SB623 cells are being applied
to treat patients with TBI (STEMTRA, NCT02416492).
MSCs have been shown to differentiate into many types of cells
from the nervous system, including dopamine neurons,111 acetylcho-
line-secreting motor neuron-like cells,112 cholinergic-like neurons,113
GABAergic neurons,114 and oligodendrocytes.115 However, the func-
tionality of these cells, manifested by, for example, the ability of the
cells to be engrafted into recipient models and to form connections
with existing circuits, remains controversial. Notably, the conditions
required to force MSCs to differentiate into neuronal cells necessitate
the presence of factors, such as 5-aza-deoxycytidine, that are not nat-
urally found in living organisms. On the other hand, priming the MSCs
to a neural phenotype may pronounce the therapeutic effect of MSCs
alone. The differentiation potential of MSCs can be exploited during
their preparation before transplantation. It was shown in a PD model
that neuro-primed MSCs have an enhanced restorative effect.116,117
Such an effect was also observed in MSCs that were primed by over-
expression of Lmx1α and neurturin, which are important factors for
differentiation and survival of dopaminergic neurons.118 Another
method of genetic priming features overexpression of neurogenin 1
(Ngn-1) in MSCs. These cells have pronounced therapeutic effects in
a mouse model of ALS and brain ischemia in comparison to
unmodified MSCs.119,120 Although MSCs overexpressing Ngn-1
exhibited neuron-like characteristics in these studies, all transplanted
cells vanished within 8 weeks. Additionally, the authors have not yet
evaluated the electrophysiological recordings of MSCs after transplan-
tation, which will support their claims. Other preclinical studies have
also demonstrated that MSCs are more likely to differentiate into neu-
ronal-like cells when in the presence of other neuronal cells.121
3.6 | MSCs cotransplantation with other cells
MSCs can also be immunosuppressive in xenotransplantation models.
Intrastriatal cotransplantation of syngeneic MSCs with porcine neuro-
blasts into 6-OHDA unilaterally lesioned rats resulted in successful
neural stem cells grafting in four out of six rats.122 Beyond changes at
the cellular level, motor recovery was also observed due to transplan-
tation. This result suggests that MSCs can be used in xenotransplanta-
tion instead of immunosuppressants, for example, cyclosporin A,
which cause side effects and are not able to protect long-lasting
grafts. On the other hand, in rat models of PD, it has been shown that
human MSCs can evoke inflammation after transplantation. This may
be due to differences between the characteristics of syngeneic and
xenogeneic transplanted MSCs. These data suggest that the immuno-
modulatory effect can be inefficient in xenotransplanted MSCs or that
other mechanisms were triggered in those studies.
The aforementioned interactions of MSCs with diseased nervous
tissue, including modulation of inflammation and neurogenesis by
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MSCs, seem to be the key to modifying the environment to pursue
regeneration (Figure 1). The multimodal activity of transplanted MSCs
in models of neurodegenerative diseases has led not only to a patho-
physiological view of the course of disease but also, in some cases, to
a therapeutic effect, such as better cognitive outcomes in models of
AD, better motor activity in models of PD and ALS or a decrease in
the amount and severity of recurrent seizures in epilepsy.119 Under-
standing which conditions are crucial to boost efficiency by optimizing
the route, time and number of administrations of MSC transplanta-
tions in preclinical models will improve our knowledge and enhance
translation into clinical trials.
4 | CLINICAL TRIALS
Selected clinical trials using MSCs to treat neurodegeneration and
brain injury are presented in Table 1. In the numerous presented stud-
ies, expanded ex vivo autologous MSCs were transplanted. However,
in a clinical trial for CP, neural-primed autologous MSCs were used,
and allogeneic administration of the previously mentioned SB623 cells
in stroke patients has been described.
The majority of clinical trials have shown the safety of a variety
of MSC applications. Severe side effects were noted when cells were
transplanted during stereotactic surgery in TBI patients.123 Neverthe-
less, most adverse events were correlated with the conducted proce-
dure, and none of them were followed with sequelae. Side effects
(spasticity, neuropathic pain, and encephalomyelitis) were also
observed in a trial performed by Kishk et al., although the American
Spinal Injury Association (ASIA) scales of the patients were rated
down from type A to type B.124 In a study by Ra et al., the authors
reported adverse effects following transplantation in all patients
enrolled in the study, although their electrophysiological (somatosen-
sory evoked potential [SSEP] and motor evoked potential [MEP])
recordings were not significantly different than before implanta-
tion.125 In most of the studies, the safety and efficiency of therapies
were assessed additionally by magnetic resonance imaging
(MRI).110,124-139 No significant anatomical, structural, or parenchymal
abnormalities or tumor formation were observed.
In most of the studies, bacterial tests were
performed.123,125,127,130,133-138,140,141 In the majority of studies, kar-
yotype analysis was also carried out.123,125,128,130,132,136-138,140 Addi-
tionally, the differentiation potential of MSCs was assessed in a few
clinical studies.125,130,131,136,138,140,142 Only in a minority of studies
parallel testing in animals was conducted.143,144 In some clinical trials,
safety evaluation was performed, proving the lack of tumorigenicity
of MSCs after administration to immunodeficient mice via subcutane-
ous or intraspinal transplantations.125,136
Transplantation of MSCs resulted in neurologic improvement in
the majority of clinical trials. Superior performance in activities of daily
living (in TBI, stroke, and SCI) and motor recovery (in TBI, stroke, CP,
and SCI) was noted. In clinical studies in groups of patients with SCI,
significant improvements were observed in sensory level and motor
function, as well as in general outcome with the ASIA scale.124,128,142
Tian et al. demonstrated that in TBI patients in a vegetative state, con-
sciousness improved after MSC transplantation.145 In patients with
MS, a tendency toward a decline in active inflammation processes and
stabilization of disease progression was observed.130,131 An enormous
improvement has been noted in patients diagnosed with DRE, in
whom transplantation of autologous MSCs resulted in amelioration of
epileptic incidences.132 This suggests a profound role of MSCs in the
repair of epileptic brains.132,141 Modest outcomes have been noted in
clinical trials with PD patients, in whom only slight improvements in
the Unified Parkinson's disease rating scale scale were obtained. How-
ever, most patients claimed subjective marginal improvement of
symptoms.137
In several studies, slight changes on neuroimaging were noted.
Steinberg et al. reported signal changes on T2 fluid attenuation inver-
sion recovery (FLAIR) MRI (13/18) and in the number of contrast-
enhancing areas (15/18) in stroke patients 1 or 2 weeks after trans-
plantation.110 Moreover, they found a significant correlation between
these changes and clinical outcomes at the 12-month follow-up.
Slight changes on MRI were observed in a study performed by
Bang et al. Researchers noticed less prominent atrophic changes fol-
lowing stroke in the MSC-treated group than in the control group.133
Honmou et al. found a reduction in infarct size on FLAIR MRI in 7
out of 12 stroke patients after treatment.135 However, because of the
lack of a control group in this study, the authors cannot exclude sponta-
neous recovery as a cause for changes in infarct size. Nevertheless, they
also noted a significant correlation between neuroimaging results and
mean changes in the National Institutes of Health Stroke Scale score.
In a study by Lee et al., researchers noted a correlation between
clinical improvements of stroke patients and SVZ damage defined by
diffusion MRI.134 They noticed a relationship between less SVZ dam-
age and clinical improvement in the MSC-treated group of patients
F IGURE 1 Therapeutic mechanisms of mesenchymal stem cells
(MSCs) in the nervous system. Source: Servier Medical Art, modified.
BBB, blood-brain barrier




























































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































MESENCHYMAL STEM CELLS AS NEURAL THERAPEUTICS 1181
but did not see this relationship in the rest of the groups (MSC-
treated patients with more SVZ damage and corresponding controls).
Moreover, they determined SDF-1α levels in patient plasma at the
time of first transplantation. Their analysis revealed a significant corre-
lation between SDF-1α plasma levels and patient outcome, defined as
scores on the Barthel index and modified Rankin scale.
Currently, there are two ongoing clinical trials concerning the
application of autologous MSCs in stroke, one of which is a random-
ized, controlled, and observer-blinded trial. The detailed methodology
of these studies has already been published.146,147
In clinical trials concerning patients with SCI, Park and colleagues
reported for the first time improvement on electrophysiological
results, assessed by SSEP and MEP recordings, and MRI examina-
tion.148 This improvement may be related to several factors. Direct
administration of MSCs into the site of injury is a more effective
method for SCI recovery than intrathecal injection. On the other hand,
three patients from the group who showed motor recovery had an
incomplete SCI with residual neurological function.
In a study by Jarocha et al. concerning one patient with total SC
interruption at the Th2-3 level, muscle strength at the left lower
extremity improved from plegia to deep paresis (1 on the Lovett
scale). Moreover, the ability to move her lower extremities against
gravity supported by the movements in her quadriceps was restored.
Neurophysiologic examination including electromyography, electro-
neurography SEP, and MEP recordings objectively confirmed the
improvement. Moreover, MRI demonstrated restoration of spinal cord
continuity.128
In a study concerning the application of MSCs in MS, Bonab et al.
showed that one intrathecal injection of autologous MSCs in patients
with secondary progressive MS resulted in stabilization of MRI find-
ings in approximately 70% of participants. As the authors underlined,
these results are very appealing in comparison to those gained from
standard pharmacological treatments with interferon beta-1a and
mitoxantrone.131 MRI studies were also performed to separate the
“honey-moon effect” from the real effect of the therapy. Interestingly,
the results obtained by Bonab et al. showed that 1 year after trans-
plantation of cells, new lesions started to appear on MRI but without
clinical manifestations. This observation may be caused by the
diminishing effect of therapy with time and stresses the necessity of
repeated transplantations.
In the study by Connick et al., researchers proposed a new
approach to measure therapeutic outcome after single intravenous
administration of autologous MSCs by assessing functioning of the
anterior visual pathway.130 They showed that visual evoked response
latency and an increase in optic nerve area appeared as a result of the
improvement in visual acuity from the applied therapy. Despite the
important conclusions from the above clinical trials, the lack of a control
group of patients is a major drawback of these studies.
In fact, in a randomized placebo-controlled phase II trial per-
formed by Llufriu et al., therapeutic effects were seen in only groups
treated with MSCs.129 Compared with the placebo group, the MSC-
treated group had changes in the mean cumulative number of gadolin-
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Th1 lymphocytes in blood; however, none of the differences was sta-
tistically significant. These observations underline the importance of
controlled studies with larger groups of enrolled patients, especially
for testing MSC therapies in diseases with unstable clinical perfor-
mance, as is the case for MS.
Only some studies have implemented repeated transplantation of
MSCs.123,126,128,132,140,141 In other studies, deterioration of the clini-
cal status of patients was noted, which may have been due to the sin-
gle MSC administration.131
As shown above, MSCs ameliorate functional deficits in several cen-
tral nervous system diseases in both experimental animal models and in
the clinic. Therapeutic mechanisms may include neuroprotective effects,
immunomodulation, tissue remodeling, and activation of local progeni-
tors. Therefore, MSCs prepare the environment for axonal ingrowth,
stimulate angiogenesis, and result in functional recovery.
5 | DISCUSSION AND FUTURE REMARKS
Growing knowledge about MSC regenerative potential raises great
hopes for applying them in the clinic. However, there is still space for
improvement, and more preclinical studies have to be performed to
evaluate cell culture conditions, the potential for neuronal priming,
and the timing and route of administration to obtain the best improve-
ments for patients.
First, there is a lack of consistent data showing the optimal source
of MSCs for transplantation. As shown in basic studies, MSCs can dif-
fer between sources in their regenerative potential, as shown by, for
example, the different levels of secreted trophic factors or the pro-
pensity of cells to differentiate toward different lineages. However,
there are many discrepancies between published data on the proper-
ties of BM-, AT-, and WJ-MSCs. Therefore, a comprehensive study is
needed to obtain reliable results. Such inquiry could also improve cell
preparation methods for clinical trials and define optimal cell culture
conditions. Another issue is the reported differences between MSCs
from healthy donors and MSCs from diseased patients that could
influence the final outcomes of therapies.44 More detailed studies are
also needed to obtain a consensus on this phenomenon.
Second, similar numbers of transplanted cells have led to
improved clinical outcomes in neurological disorders. However, there
is a lack of comprehensive studies discussing these issues by evaluat-
ing different doses in one clinical study.
F IGURE 2 Schematic overview of the most essential aspects of mesenchymal stem cell (MSC)-based cell therapies in treatment of nervous
system diseases. Created with BioRender.com
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Another issue is a lack of consensus for the best MSC transplan-
tation method. Intravascularly transplanted MSCs may become
trapped in the lungs and liver, from which they can release micro-
vesicles and immunomodulative factors.56 In some preclinical studies,
such entrapment resulted in serious side effects, such as increased
risk for iatrogenic atelectasis and lethal pulmonary thromboembolism;
however, such observations were made when MSCs were
transplanted into healthy animals.149 In those animals, active migra-
tion of MSCs cannot be enhanced, so the cells inertly accumulate in
the lungs. In many studies (in stroke and MS), intravascular administra-
tion of MSCs despite their presence near the injury area has a signifi-
cant influence on outcome after treatment.129,130,133 This suggests
that MSCs can influence inflammation in the brain through the periph-
eral circulatory system. However, the residual presence of MSCs can
also be caused by their migration and poor survival in the nervous sys-
tem. In contrast, studies have shown the presence of MSCs in the ner-
vous system for up to 8 weeks, which could be long enough to exert
therapeutic effects.119
Invasive ways of transplantation of MSCs can provoke many side
effects and potentially enhance inflammation in the nervous system,
which can (a) cause additional changes in the nervous system and/or
(b) diminish therapeutic potential. Therefore, intrathecal implementa-
tion of MSCs can transplant them directly to cerebrospinal fluid with-
out any significant adverse effects. On the other hand, SCI clinical
trials have shown that the best results occur when MSCs are
transplanted directly into damaged tissue. However, our clinical trials
have shown that intrathecal implementation can also be very success-
ful.128,132 Therefore, the combination of intrathecal and intravenous
administration can be considered an effective way to modulate the
environment inside the nervous system as well as the adaptive
immune response. Importantly, both of these methods of transplanta-
tion can be used for repeated injections.
As shown in clinical and preclinical studies, the mainstays of MSC
regenerative potential are the capabilities for immunomodulation and
secretion of many trophic factors. Therefore, multiple injections can
provide continuous stimulation for repair.123,126,128,132,140,141 Several
clinical trials have shown that repeated transplantations of cells are
beneficial for patient outcome, which necessitates the standardization
of a reasonable cell injection strategy. In our hands, such a method
seems to be intrathecal injection, which is also popular in other stud-
ies.128,132 Although some side effects may appear, there is no danger
to patient health or life. Moreover, this route of administration has
undoubted advantages in being transplanted directly to the nervous
system, allowing the cells to easily migrate to regions of degeneration.
Nonetheless, because some studies reported complications after this
type of administration, such an approach still remains to be evaluated.
Less invasive methods of MSC transplantation might be intranasal
injections; however, to date, this method of injection has only been
evaluated in clinical studies for drug administration.150
As mentioned above, the trophic character of MSCs underlies
clinical improvement in patients. It was also shown in preclinical stud-
ies that MSCs are present up to weeks after transplantation, and this
time is sufficient for promotion of neurogenesis in adult mice with
HD.151 The issue, which fortunately is being evaluated, is whether
MSCs in fact can engraft and differentiate into neurons and replace
the lost ones. As studied in MSCs overexpressing Ngn-1, modified
MSCs have enhanced electrophysiological characteristics, and some
of them show neuronal-like characteristics after transplantation. Nev-
ertheless, it cannot be claimed that MSCs transdifferentiate into neu-
rons. Additionally, the cells disappear after 8 weeks. To date, no study
has performed electrophysiological tests on transplanted MSCs with
neuronal-like characteristics. Though studies have claimed that modi-
fication of MSCs or priming can enhance neuronal-like features, call-
ing those cells neurons, without a proper battery of tests, is incorrect.
Another emerging issue is related to the necessity of side-to-side
clinical and preclinical studies. Such an approach has been
implemented in only a minority of clinical studies.143,144 This type of
scientific approach is of necessary to not only identify potential
improvements but also ensure solid scientific methods are being
employed to explain observed phenomena.
It is also worth mentioning that the discrepancy between preclinical
and clinical trials can be caused by the selection of patients in clinical tri-
als. Unfortunately, because there are still not well-standardized proce-
dures concerning MSC transplantation, patients enrolled in clinical trials
are usually incurable by every other common method or their disorder
has lasted for a long time. The abovementioned reasons can diminish
the clinical outcomes in patients in clinical trials in comparison to those
seen in preclinical trials. This also addresses the problem of the best
therapeutic window. It was shown in vast of preclinical studies that
MSC transplantation shortly after injury is most promising for obtaining
the greatest therapeutic effect.152,153 This is especially crucial for neu-
rological disorders such as stroke, TBI, SE or SCI, in which there is no
time to obtain and expand autologous MSCs from patients. Currently,
this approach is not possible in clinical trials. In the future, cell banks can
store ready-made products to be transplanted in an allogeneic manner.
It has been shown in preclinical studies that one of the ways to
enhance the positive impact of MSCs on the repair of the nervous
system is to modify them with trophic factors. For safety reasons,
allogeneic transplantations will be the first choice. In other cases, in
vitro priming of autologous MSCs can also be efficient, which has
been shown in CP clinical trials.136 Detailed in vitro studies combined
with in vivo testing are needed to evaluate standardized protocols of
such priming/modification strategies. The effect of modification must
be profound to risk transplantation of genetically modified cells in
clinical studies. However, as shown in studies using the stable SB623
cell line, the usage of such cells can be safe and may increase the ther-
apeutic potential of MSCs.106,109,110
6 | CONCLUSIONS
Published results of MSC transplantation in various neurological dis-
eases, especially in clinical trials, show that MSCs have great potential
to improve patient symptoms and quality of life, whereas traditional
medicine offers no efficient treatment. However, the design of experi-
ments within clinical studies and preclinical studies leaves vast space
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for reasonable criticism of the regenerative potential of MSCs. There-
fore, more consistent evaluation of MSCs is needed. Taking into con-
sideration the multimodal characteristics of MSCs, studies evaluating
their role in repair should also consider such characteristics. More
advanced and parallel methods should be involved, such as proteome
and secretome studies, in vitro and in vivo functional studies and
strictly controlled preclinical studies (Figure 2). As it is difficult to
implement a placebo control in clinical trials, especially in pediatric dis-
eases, there is a great need to perform detailed studies in preclinical
trials involving advanced methodology and focusing on a deep under-
standing of the mechanism of the therapeutic potential of MSCs.
Therefore, multidisciplinary studies involving clinicians and scientists
from various specialties can pave a more reliable way for introducing
MSCs into the clinic. We hope that our review uniformly summarizes
both the promise and potential routes of advancement of MSCs that
can provide information for consideration by clinicians planning future
clinical trials.
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